

Opioid Dependence Therapy Agents Prior Authorization Form

Member information		
1. Member last name:	2. Member first name:	
3. Member ID #:	4. Member date of birth:	5. Member gender:
Prescriber information		
6. Prescribing provider NPI #:		
7. Prescriber contact information		
Name:		
Phone:	Ext:	
Drug information		
8. Drug name:	9. Strength:	
10. Quantity per 30 days:		
11. Length of therapy (in days): <input type="checkbox"/> up to 30 days <input type="checkbox"/> 60 days <input type="checkbox"/> 90 days <input type="checkbox"/> 120 days <input type="checkbox"/> 180 days <input type="checkbox"/> 365 days		
<input type="checkbox"/> Other: _____		
Clinical information		
For coverage of Buprenorphine/Naloxone SL Films, and Zubsolv:		
1. Has the member failed one preferred drug? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Please list:		
1a. <input type="checkbox"/> Allergic reaction 1b. <input type="checkbox"/> Drug-to-drug interaction. Please describe reaction:		
2. <input type="checkbox"/> Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:		
3. <input type="checkbox"/> Clinical contraindication, co-morbidity, or unique member circumstance as a contraindication to preferred drug(s). Please provide clinical information:		
4. <input type="checkbox"/> Age specific indications. Please give member age and explain:		
5. <input type="checkbox"/> Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a general reference:		
6. <input type="checkbox"/> Unacceptable clinical risk associated with therapeutic change. Please explain:		
For coverage of buprenorphine sublingual tablets:		
7. Does the member have a diagnosis of opioid dependence? <input type="checkbox"/> Yes <input type="checkbox"/> No		
8. Is the member unable to use suboxone film? <input type="checkbox"/> Yes <input type="checkbox"/> No		
If yes , please specify one or more of the following conditions:		
<input type="checkbox"/> Member is pregnant: Please provide estimated due date: _____ Max length of therapy is 270 days.		
<input type="checkbox"/> Member is breast feeding Max length of therapy is 60 days (can be renewed).		
<input type="checkbox"/> Member has an allergy to naloxone (rashes, hives, pruritis, bronchospasm, angioneurotic edema, and anaphylactic shock) Max length of therapy is 365 days.		
<input type="checkbox"/> Other condition. Please list:		
9. Has the prescriber reviewed the controlled substances reporting system database prior to writing the prescription to ensure that concomitant opioid use is not occurring? <input type="checkbox"/> Yes <input type="checkbox"/> No		
10. Is the maximum daily dose less than or equal to 32 mg/day? <input type="checkbox"/> Yes <input type="checkbox"/> No		
For coverage of Lucemyra tablets:		
11. Does the beneficiary have a diagnosis of opioid withdrawal symptoms? <input type="checkbox"/> Yes <input type="checkbox"/> No (trial and failure of preferreds are not required)		

<https://provider.healthybluenc.com>

Healthy Blue is a Medicaid plan offered by Blue Cross and Blue Shield of North Carolina. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross Blue Shield Association. ® Marks of the Blue Cross Blue Shield Association. All other marks are the property of their respective owners.

NCHB-CD-052760-24-SRS52523 March 2024

Healthy Blue
Opioid Dependence Therapy Agents

Signature of prescriber:

Date:

(Prescriber signature mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to **844-376-2318**.
Healthy Blue Pharmacy PA Call Center: **844-594-5072**